期刊
BIOTECHNOLOGY JOURNAL
卷 8, 期 3, 页码 371-382出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/biot.201200363
关键词
Erythropoietin; Glycoengineering; Plants; Purification; Sialylation
资金
- Laura Bassi Centres of Expertise [822757]
- Fonds zur Forderung der wissenschaftlichen Forschung FWF [L575-B13]
- Austrian Science Fund (FWF) [L575] Funding Source: Austrian Science Fund (FWF)
- Austrian Science Fund (FWF) [L 575] Funding Source: researchfish
Recombinant human erythropoietin (rhEPO), a glycohormone, is one of the leading biopharmaceutical products. The production of rhEPO is currently restricted to mammalian cell expression systems because of rhEPO's highly complex glycosylation pattern, which is a major determinant for drug-efficacy. Here we evaluate the ability of plants to produce different glycoforms of rhEPO. cDNA constructs were delivered to Nicotiana benthamiana (N. benthamiana) and transiently expressed by a viral based expression system. Expression levels up to 85 mg rhEPO/kg fresh leaf material were achieved. Moreover, co-expression of rhEPO with six mammalian genes required for in planta protein sialylation resulted in the synthesis of rhEPO decorated mainly with bisialylated N-glycans (NaNa), the most abundant glycoform of circulating hEPO in patients with anemia. A newly established peptide tag (ELDKWA) fused to hEPO was particularly well-suited for purification of the recombinant hormone based on immunoaffinity. Subsequent lectin chromatography allowed enrichment of exclusively sialylated rhEPO. All plant-derived glycoforms exhibited high biological activity as determined by a cell-based receptor-binding assay. The generation of rhEPO carrying largely homogeneous glycosylation profiles (GnGnXF, GnGn, and NaNa) will facilitate further investigation of functionalities with potential implications for medical applications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据